Editorial: Toxins 2015
BUDGET IMPACT ANALYSIS OF BOTULINUM NEUROTOXIN A THERAPY FOR UPPER LIMB SPASTICITY IN THE UNITED KINGDOM
INTERACTION OF A NOVEL CYCLIC PEPTIDE INHIBITOR WITH BOTULINUM NEUROTOXIN A LIGHT CHAIN: INSIGHTS FROM X-RAY CRYSTALLOGRAPHY
FOCAL DYSTONIAS: RATING SCALES
BLEPHAROSPASM AND MEIGE SYNDROME: ARE THERE ANY DIFFERENCES?
ULTRASOUND GUIDANCE FOR BOTULINUM TOXIN INJECTIONS
USE OF GAIT LAB STUDIES IN LOWER EXTREMITY DYSTONIA TO IDENTIFY MUSCLES FOR INJECTION
TREATING PRIMARY AND SECONDARY CERVICAL DYSTONIA
AN EXPLORATORY, SINGLE-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 16-WEEK STUDY OF THE EFFICACY AND SAFETY OF INTRA-ARTICULAR ONABOTULINUMTOXINA (ONABOTA, 200 U) AS TREATMENT FOR OSTEOARTHRITIS KNEE PAIN: RESULTS FROM EXPERIMENTAL PAIN MODELS
EFFICACY AND SAFETY OF A READY-TO-USE LIQUID FORMULATION OF ABOBOTULINUMTOXINA LYOPHILISATE IN MODERATE TO SEVERE GLABELLAR LINES: RESULTS OF A PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL
MOLECULAR BASIS OF IMMUNOGENICITY TO BOTULINUM NEUROTOXINS
FUNCTIONAL CHARACTERIZATION OF BONT/A SUBTYPES
SHINING THE LIGHT ON BOTULISM: ENZYME ACCELERATION, FLUORESCENT AND BIOLUMINESCENT TOXIN DETECTION
RECOMBINANT DERIVATIVES OF BOTULINUM NEUROTOXINS: SHOULD DERIVATIVES WITH LIGHT CHAIN INACTIVATING MUTATIONS RETAIN BIOLOGICAL ACTIVITY?
THE SOUTH AMERICAN GLABELLAR EXPERIENCE STUDY (SAGE): A MULTICENTER RETROSPECTIVE ANALYSIS OF REAL-WORLD TREATMENT PATTERNS FOLLOWING THE INTRODUCTION OF INCOBOTULINUMTOXINA IN ARGENTINA
MULTIPLE DOMAINS OF TETANUS TOXIN DIRECT ENTRY INTO PRIMARY NEURONS
SEVERE DYSPHAGIA OF SPASTIC UPPER ESOPHAGEAL SPHINCTER FOLLOWING ENCEPHALITIS TREATED WITH HIGH DOSES OF INCOBOTULINUMTOXINA (XEOMIN NT 201): A CASE REPORT
CLINICAL DISTINCTIONS BETWEEN ESSENTIAL AND DYSTONIC VOICE TREMOR
USE OF BOTULINUM NEUROTOXIN TYPE A (XEOMIN) INJECTIONS TO THE PERINEAL MUSCLES IN CASES OF PERINEAL PAIN AND DYSFUNCTION ASSOCIATED WITH PELVIC FLOOR MUSCLE OVERCONTRACTION AND MYALGIA
ASSAY FOR IN-VITRO DETERMINATION OF THE POTENCY OF BOTULINUM NEUROTOXINS
THE NEED FOR CLINICAL SAFETY AND EFFICACY DATA ON HIGH-DOSE BOTULINUM NEUROTOXIN TREATMENT FOR PATIENTS WITH SPASTICITY
CLINICAL DIFFERENCES BETWEEN BOTULINUM NEUROTOXIN TYPE A AND B TOXINS
IS THERE ONE TOXIN FORMULATION OR DOSE THAT IS SUPERIOR TO ANOTHER FOR BLEPHAROSPASM/HEMIFACIAL SPASM?
PREDICTIVE PARAMETERS FOR THE EFFECT OF BOTULINUM NEUROTOXIN INFILTRATIONS IN CHRONIC MIGRAINE
MANAGING DROOLING IN CEREBRAL PALSY
FUNCTIONAL NETWORK- AND SYNAPSE-LEVEL RESPONSES TO BOTULINUM NEUROTOXIN TYPE A IN STEM CELL-DERIVED NEURONS: A RAPID AND ULTRA-SENSITIVE CELL-BASED PLATFORM
DIFFERENCES IN THE MANAGEMENT OF CERVICAL DYSTONIA IN THE UNITED STATES (US) VERSUS EUROPE (EU): THE PATIENTS' PERSPECTIVE
A NEW ANTERIOR ACCESS FOR SUBSCAPULAR MUSCLE BOTULINUM TOXIN INJECTION
TREATMENT OF LARYNGEAL DISORDERS AND OROMANDIBULAR DYSTONIA: TECHNIQUES OF LOCALIZATION AND DOSING
A NEW, SYMPTOM-BASED APPROACH TO NEUROLOGIC GAIT DISORDERS
THE DURABILITY OF ONABOTULINUMTOXINA FOR THE TREATMENT OF CHRONIC MIGRAINE: CLARITY PILOT STUDY
STANDARD OF PRACTICE IN ANTICOAGULATED INDIVIDUALS REQUIRING DEEP COMPARTMENT BOTULINUM NEUROTOXIN INJECTIONS FOR SPASTICITY: A SURVEY
SPASTICITY: RATING SCALES
SPASTICITY WORKSHOP
ONABOTULINUMTOXINA REDUCES PAIN IN PATIENTS WITH UPPER LIMB POSTSTROKE SPASTICITY
PREGNANCY OUTCOMES FOLLOWING EXPOSURE TO ONABOTULINUMTOXINA
DUAL MECHANISTIC EFFECTS OF ONABOTULINUMTOXINA (ONABOTA) ON EFFERENT AND AFFERENT NEURONS
A LITERATURE SURVEY OF RANDOMIZED, SINGLE- AND DOUBLE-BLIND CLINICAL STUDIES ON BRANDED BOTULINUM NEUROTOXINS
UPTAKE AND RELEASE OF BOTULINUM NEUROTOXIN BY PRIMARY NEURONS
CLINICAL ASPECTS OF PARKINSON'S DISEASE THAT CAN BE TREATED WITH BOTULINUM TOXIN
EFFICACY AND SAFETY PROFILE OF INCOBOTULINUMTOXINA IN CHILDREN WITH CEREBRAL PALSY: RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL
EVOLUTION OF FACIAL AESTHETIC TREATMENT OVER 5 OR MORE YEARS: AN INTERNATIONAL, RETROSPECTIVE, CROSS-SECTIONAL ANALYSIS OF CONTINUOUS ONABOTULINUMTOXINA TREATMENT
LONG-LASTING FUNCTIONAL BRAIN CHANGES IN A CASE STUDY OF CERVICAL DYSTONIA TREATED WITH BOTULINUM TOXIN AND MOTOR RELEARNING TECHNIQUES
BOTULINUM TOXIN IN UROLOGY
THE EXPERIENCE WITH BOTULINUM TOXIN INJECTIONS IN 26 PATIENTS WITH WRITER'S CRAMP
AN INTERNATIONAL, PROSPECTIVE COHORT TO DOCUMENT THE EFFECTIVENESS OF 1 CYCLE OF BONT/A BASED ON ATTAINMENT OF INDIVIDUAL PERSON-CENTERED GOALS IN ADULT SUBJECTS SUFFERING FROM UPPER LIMB SPASTICITY FOLLOWING STROKE (ULIS II): SUBANALYSIS OF THE SOUTH ASIAN GROUP OF SPASTICITY PATIENTS
STUDYING F(AB')2 ANTITOXINS DERIVED FROM EQUINE IGG AGAINST BOTULINUM NEUROTOXINS
BOTULINUM TOXIN INJECTION TO THE UPPER LIMB INDIRECTLY IMPROVES GAIT IN PATIENTS WITH POSTSTROKE SPASTICITY
CAMPTOCORMIA
INTEREST IN CD2 – AN ONGOING 3-YEAR FOLLOW-UP STUDY OF CERVICAL DYSTONIA: BASELINE INTERIM ANALYSIS, INCLUDING PATIENT SATISFACTION WITH TREATMENT
TREATMENT PATTERNS AND PATIENT DISPOSITION IN THE CERVICAL DYSTONIA PATIENT REGISTRY FOR OBSERVATION OF ONABOTULINUMTOXIN A EFFICACY (CD PROBE)
THE MANY CAUSES OF SECONDARY NONRESPONSE TO BOTULINUM TOXIN TREATMENT
CLINICAL PEARLS: OPTIMIZING OUTCOMES IN BLEPHAROSPASM AND HEMIFACIAL SPASM—HOW TO INJECT FOR OPTIMAL OUTCOMES
PHARMACODYNAMIC COMPARISON OF 3 MARKETED BOTULINUM NEUROTOXIN TYPE A PRODUCTS
INJECTION TECHNIQUES
CELL BIOLOGY OF THE NEURON: MEMBRANE LIPID DYNAMICS IN THE REGULATION OF SYNAPTIC FUNCTION
ABOBOTULINUM AND INCOBOTULINUM TOXINS TYPE A ANALGESIC EFFECT IN CENTRAL POSTSTROKE PAIN WITH ALLODYNIA: 2 CASE REPORTS
THE USE OF ELECTROMYOGRAPHY IN BOTULINUM TOXIN TREATMENT OF CERVICAL DYSTONIA
EFFECTIVENESS OF BOTULINUM TOXIN A (BONT-A) IN ADULTS WITH POST-STROKE LOWER LIMB SPASTICITY IN SPAIN: GOAL ATTAINMENT AFTER ONE INJECTION CYCLE
DIAGNOSIS OF BLEPHAROSPASM: ARE WE THERE YET?
DEVELOPMENT OF AN ENRICHED AND HIGHLY BONT/A1-SENSITIVE MOTOR NEURON CULTURE
ABOBOTULINUMTOXINA IN THE MANAGEMENT OF CERVICAL DYSTONIA (CD) IN THE UNITED KINGDOM (UK): A BUDGET IMPACT ANALYSIS (BIA)
ECONOMIC MODELING OF THE USE OF BOTULINUM TOXIN A IN A HOMOGENOUS PATIENT POPULATION IN REAL-LIFE CLINICAL PRACTICE: ULIS-II (THE UPPER LIMB INTERNATIONAL SPASTICITY STUDY)
BOTULINUM NEUROTOXIN THERAPY: REDUCTION OF INJECTION SITE PAIN BY PH NORMALIZATION
BOTULINUM NEUROTOXIN THERAPY OF CERVICAL DYSTONIA: DURATION OF THERAPEUTIC EFFECTS
EFFICACY OF INCOBOTULINUMTOXINA IN POSTSTROKE UPPER LIMB SPASTICITY: RESULTS FROM A LARGE MULTICENTER 1-YEAR NONINTERVENTIONAL STUDY
MOUSE DIAPHRAGM ASSAY CONFIRMS IDENTICAL POTENCY LABELING FOR ONABOTULINUMTOXINA (BOTOX) AND INCOBOTULINUMTOXINA (XEOMIN)
ECONOMICS OF BOTULINUM TOXIN THERAPY: INFLUENCE OF THE ABOBOTULINUMTOXINA PACKAGE SIZE ON THE COSTS OF BOTULINUM NEUROTOXIN THERAPY
BOTULINUM TOXIN THERAPY OF CERVICAL DYSTONIA: COMPARING ONABOTULINUMTOXINA (BOTOX) AND INCOBOTULINUMTOXINA (XEOMIN)
ASSESSING ANTIBODIES TO BOTULINUM TOXIN
PAINFUL LEG AND MOVING TOES SYNDROME TREATED WITH BOTULINUM NEUROTOXIN TYPE A: A VIDEO CASE REPORT
AVERAGE DOSE OF BOTULINUM NEUROTOXIN A (BONT/A) INJECTED INTO PATIENTS IN REAL LIFE (PHYSICIAN's PRACTICE)
THE POTENTIAL FOR TARGETED SECRETION INHIBITORS (TSIS) IN THE TREATMENT OF CANCER
RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY INVESTIGATING THE SAFETY AND EFFICACY OF XEOMIN IN TREATING POSTSTROKE SPASTICITY OF THE UPPER LIMB
THE BILAYER-BASED ASSAY FOR BOTULINUM POTENCY ASSESSMENT
CERVICAL DYSTONIA
CONTROVERSIES ON UNRESOLVED ISSUES IN THE USE OF BOTULINUM NEUROTOXINS: THE APPLICATION OF BOTULINUM NEUROTOXIN FOR HEMIPARETIC GAIT
EXPERIENCE MAKES A DIFFERENCE: DATA FROM THE PATIENT REGISTRY OF OUTCOMES IN SPASTICITY (PROS) CARE WORLD
SPATIOTEMPORAL CHANGES IN GAIT PERFORMANCE DUE TO ONABOTULINUMTOXINA INJECTION TO LOWER LIMB MUSCLES IN PATIENTS WITH UPPER MOTOR NEURON SYNDROME
IS THE ANALGESIC MECHANISM OF ACTION OF BOTULINUM NEUROTOXIN TYPE A IN RATS UNEQUIVOCAL?
SHORTENED INTERVALS BETWEEN INJECTIONS
ADJUNCTIVE TREATMENTS FOR SPASTICITY
FEASIBILITY OF AN INTERNATIONAL NETWORK-BASED APPROACH TO IMPROVE CURRENT PRACTICE OF BOTULINUM TOXIN INJECTIONS FOR CERVICAL DYSTONIA AND SPASTICITY
USE OF CONCOMITANT THERAPIES IN REAL-LIFE CLINICAL MANAGEMENT OF PATIENTS WITH POSTSTROKE UPPER LIMB SPASTICITY TREATED WITH BOTULINUM TOXIN: GERMAN-AUSTRIAN SUBGROUP OF THE ULIS II STUDY
THERAPEUTIC GOAL ASSESSMENT IN SPASTICITY AFTER BOTULINUM TOXIN TYPE A INJECTION IN THE SPANISH POPULATION: THE 5E STUDY
BOTULINUM TOXIN AND THE TREATMENT OF HEADACHE: AN EVIDENCE-BASED REVIEW
ANTEROCOLLIS AND ANTEROCAPUT
BOTULINUM NEUROTOXIN TRANSLOCATION DOMAIN: A MOLECULAR DISSECTION OF FUNCTION
RODENT- AND HUMAN-DERIVED CELL-BASED MODELS FOR THE STUDY OF BOTULINUM NEUROTOXIN A1 (BONT/A1)
PRACTICAL APPLICATIONS FOR CERVICAL DYSTONIA AND BLEPHAROSPASM
PRESENCE OF CLOSTRIDIAL DNA IN BOTULINUM TOXIN PRODUCTS
MUSICIANS' DYSTONIA: A WINDOW ON MOTOR CONTROL
BOTULINUM NEUROTOXIN A COMPLEX EXPLOITS INTESTINAL M CELLS TO ENTER THE HOST
AESTHETIC USE OF BOTULINUM NEUROTOXIN: OPTIONS AND OUTCOMES
BOTULINUM TOXIN INJECTIONS FOR HYPERHIDROSIS: EFFICACY AND SIDE EFFECTS
PAIN, SENSORY SYSTEM, AND CENTRAL EFFECTS: BOTULINUM TOXIN AND PRIMARY HEADACHE DISORDERS
WRITER's CRAMP
BASELINE CHARACTERISTICS OF ADULT PATIENTS WITH LOWER LIMB SPASTICITY INCLUDED IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF 2 DOSES OF ABOBOTULINUMTOXINA (DYSPORT)
ABOBOTULINUMTOXINA (DYSPORT) IN THE TREATMENT OF ADULTS WITH UPPER LIMB SPASTICITY IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
EXPLANATION OF TIMING OF BOTULINUM NEUROTOXIN EFFECTS, ONSET, AND DURATION, AND CLINICAL WAYS OF INFLUENCING THEM
CHILDREN ARE NOT LITTLE ADULTS—DOSAGE AND DEVELOPMENT DO MATTER
GENETIC DIVERSITY AMONG BOTULINUM NEUROTOXIN-PRODUCING BACTERIA AND THEIR NEUROTOXINS
EVIDENCE-BASED REVIEW: LARYNGEAL DYSTONIA—ABDUCTOR, ADDUCTOR, AND VOCAL TREMOR
THICKNESS OF GASTROCNEMIUS MUSCLE IN AMBULATORY CHILDREN WITH CEREBRAL PALSY
PROCESS DEVELOPMENT AND CGMP MANUFACTURE OF A TARGETED SECRETION INHIBITOR: A NOVEL BOTULINUM NEUROTOXIN–BASED BIOTHERAPEUTIC PLATFORM
EFFECT OF BOTULINUM NEUROTOXIN TYPE A SUBTYPES ON GUINEA PIG ISOLATED ILEUM SMOOTH MUSCLE
SAFETY AND EFFECTIVENESS OF INCOBOTULINUMTOXINA (XEOMIN) IN ADULT SUBJECTS WITH SPASTICITY PREVIOUSLY TREATED WITH ONABOLULINUMTOXINA (BOTOX)
INFILTRATION WITH BOTULINUM NEUROTOXIN A (XEOMIN) IN FLEXIBLE INTERVALS TO REACH APPROPRIATE MODULATION OF SPASTICITY
MAXIMIZING OUTCOMES IN SPASTICITY USING BONT
PAIN OTHER THAN HEADACHES
FACTORS INFLUENCING GOAL ATTAINMENT IN PATIENTS WITH POSTSTROKE UPPER LIMB SPASTICITY FOLLOWING TREATMENT WITH BOTULINUM NEUROTOXIN A IN REAL-LIFE CLINICAL PRACTICE: SUBANALYSES FROM THE UPPER LIMB INTERNATIONAL SPASTICITY (ULIS)-II STUDY
LONG-TERM EFFECTS OF BOTULINUM TOXIN INJECTIONS
BASELINE DEMOGRAPHICS AND EVALUATION OF HEALTH UTILITY IN MOVEMENT DISORDER PATIENTS RECEIVING ONABOTULINUMTOXINA (BOTOX) TREATMENT IN A PROSPECTIVE OBSERVATIONAL COHORT STUDY: MOBILITY
TREATMENT OF HEAD TREMOR WITH BOTULINUM TOXIN
CLINICAL DIFFERENCES BETWEEN A1 AND A2 BOTULINUM TOXIN SUBTYPES
FUNCTIONAL CHARACTERIZATION OF A NOVEL BOTULINUM NEUROTOXIN F/A HYBRID
STRUCTURAL BASIS FOR RECOGNITION OF SYNAPTIC VESICLE PROTEIN 2C BY BOTULINUM NEUROTOXIN A
BOTULINUM NEUROTOXIN B IN THE TREATMENT OF CRANIOFACIAL HYPERHIDROSIS
WRITER's CRAMP: INITIAL AND SUBSEQUENT INJECTIONS—HOW DO WE MODIFY THE APPROACH TO OPTIMIZE OUTCOMES?
DOSING AND RESPONSE TO BOTULINUM NEUROTOXIN AFTER DEEP BRAIN STIMULATION IN GENERALIZED DYSTONIA
A CASE STUDY OF MANAGEMENT OF UPPER EXTREMITY CLONUS USING BOTULINUM TOXIN TYPE A
CONSISTENT LONG TERM EFFICACY AND SAFETY OF REPEAT ONABOTULINUMTOXINA INJECTIONS IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY: FINAL RESULTS OF UP TO 4 YEARS' TREATMENT
TRUDOSE PILOT STUDY: AN EVALUATION OF THE DOSE OF INCOBOTULINUMTOXINA AND ONABOTULINUMTOXINA FOR THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA AND BLEPHAROSPASM
MOOD-STABILIZING EFFECT OF BOTULINUM TOXIN THERAPY IN PATIENTS WITH FOCAL DYSTONIA
ISOLATION AND FUNCTIONAL CHARACTERIZATION OF THE NOVEL CLOSTRIDIUM BOTULINUM A8 NEUROTOXIN SUBTYPE
TREMOR: ESSENTIAL AND PALATAL TREMOR
BONT/A IMMUNOGENICITY: A SYSTEMATIC REVIEW OF THE LITERATURE
DOES REDUCTION IN NUMBER OF INJECTION SITES OF ABOBOTULINUMTOXINA IMPACT EFFICACY IN NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN THE SPINAL CORD-INJURED (SCI) RAT MODEL?
MOLECULAR BASIS FOR DISRUPTION OF E-CADHERIN ADHESION BY BOTULINUM NEUROTOXIN TYPE A COMPLEX
FACIAL CONTOURING WITH THE INTRADERMAL INJECTION TECHNIQUE OF BOTULINUM NEUROTOXIN TYPE A IN ASIAN WOMEN
TECHNIQUES FOR LOCALIZING MUSCLES FOR BOTULINUM TOXIN (BONT) INJECTIONS
HUMAN ANTIBODY ENGINEERING FOR PREVENTION AND TREATMENT OF BOTULINUM NEUROTOXIN (BONT) INTOXICATION
INSIGHTS INTO THE GLYCOSYLATION-STATUS DEPENDENT INTERACTION OF SV2C WITH BOTULINUM NEUROTOXIN TYPE A
EFFECTS OF BOTULINUM TOXIN ON TREATMENT FOR SIALORRHEA IN PATIENTS WITH CEREBRAL PALSY
POTENCY ASSAY FOR BOTULINUM NEUROTOXIN TYPE A BASED ON NEURONAL CELLS AS A REPLACEMENT FOR THE MOUSE BIOASSAY
BOTULINUM TOXIN DYSTONIA OUTCOMES: COMPARING PRIMARY AND SECONDARY BLEPHAROSPASM PATIENTS
ANTINOCICEPTIVE ACTIVITY OF BOTULINUM TOXIN TYPE A IN THE RAT TRIGEMINAL REGION
ONABOTULINUMTOXINA PROPHYLAXIS IN CHRONIC MIGRAINE UTILIZATION AND PATIENT CHARACTERISTICS: OBSERVATIONAL STUDY IN THE EUROPEAN UNION
MANAGEMENT OF SPASTICITY: WHERE DOES BOTULINUM NEUROTOXIN (BONT) FIT?
THE LONG DURATION OF ACTION OF CLOSTRIDIUM BOTULINUM A5 TOXIN AT THE MAMMALIAN NEUROMUSCULAR JUNCTION
BROAD-SPECTRUM DETECTION OF ALL CLOSTRIDIAL NEUROTOXINS IN STEM CELL-DERIVED NEURONS AND IDENTIFICATION OF COMPOUNDS THAT RESCUE SYNAPTIC ACTIVITY IN SYNAPTIC FUNCTION-BASED ASSAYS
INTEREST IN CD2: BASELINE INTERIM ANALYSIS OF THE MOST FREQUENTLY INJECTED MUSCLES AND TECHNIQUES FOR CERVICAL DYSTONIA
ABOBOTULINUMTOXINA FOR CERVICAL DYSTONIA (CD): PATTERNS OF USE AND CLINICAL PRACTICES
GOAL ATTAINMENT SCALING TO IMPROVE CURRENT CLINICAL PRACTICE WITH BONT/A IN THE MANAGEMENT OF UPPER MOTOR NEURON SYNDROME IN UPPER AND LOWER LIMBS IN ADULTS
GAPS IN BASIC KNOWLEDGE OF BOTULINUM NEUROTOXINS
EFFICACY AND SAFETY OF TREATMENT WITH INCOBOTULINUMTOXINA (NT 201-XEOMIN) IN POSTSTROKE LOWER LIMB SPASTICITY
INCOBOTULINUMTOXINA (NT 201; XEOMIN) FOR THE TREATMENT OF SPASTICITY IN PATIENTS WITH MULTIPLE SCLEROSIS
SIALORRHEA TREATMENT WITH INCOBOTULINUMTOXINA ( XEOMIN ) IN NEUROLOGIC PATIENTS
VARIABLE FRAGMENT OF HEAVY CHAIN ANTIBODY (VHH)–BASED NEUTRALIZING AGENTS (VNAS) AS UNCONVENTIONAL AND VERSATILE THERAPEUTICS FOR TOXIN-MEDIATED DISEASES
CLINICAL COMPARISON OF BOTULINUM NEUROTOXIN EFFECTS AT THE NEUROMUSCULAR JUNCTION AND AUTONOMIC NERVES: SIMILARITIES AND DIFFERENCES
LONG-TERM EFFICACY AND SAFETY OF ONABOTULINUMTOXINA TREATMENT IN OVERACTIVE BLADDER SYNDROME AND URINARY INCONTINENCE: INTERIM ANALYSIS WITH MEDIAN 2.4 YEARS' FOLLOW-UP
BOTULINUM NEUROTOXIN THERAPY FOR HYPERHIDROSIS: REDUCTION OF INJECTION SITE PAIN BY NITROUS OXIDE/OXYGEN MIXTURES
AN INNOVATIVE EDUCATION PROGRAM TO INCREASE KNOWLEDGE ON THE TREATMENT AND MANAGEMENT OF SPASTICITY: DOSIS (DIAGNOSIS, OBJECTIVES, STRATEGY, INTERVENTION, SEQUENCE)
FUNCTIONAL, SOCIAL, AND PSYCHOLOGICAL CHARACTERISTICS OF PATIENTS WITH FACIAL DYSTONIAS TREATED WITH BOTULINUM TOXIN
EVALUATION OF PAIN RELIEF IN THE CERVICAL DYSTONIA PATIENT REGISTRY FOR OBSERVATION OF ONABOTULINUMTOXINA EFFICACY (CD PROBE)
GENOMICS AND EVOLUTION OF CLOSTRIDIUM BOTULINUM AND NEUROTOXINS
DIFFERENCES IN MODE OF ACTION OF THE DIFFERENT TOXINS: DISTINCT CHARACTERISTICS OF BOTULINUM NEUROTOXIN A SUBTYPES
VARIATIONS IN VAMP1 ACROSS VERTEBRATES SUGGEST A POTENTIAL SELECTIVE PRESSURE FROM BOTULINUM NEUROTOXINS
BOTULINUM TOXIN IN SIALORRHEA IS SAFE AND EFFECTIVE IN LONG-TERM USE
ADVERSE EFFECTS OF BOTULINUM NEUROTOXIN TYPE A USED FOR LIMB SPASTICITY IN CANADA
THIOREDOXIN AND ITS REDUCTASE ARE PRESENT ON SYNAPTIC VESICLES AND THEIR INHIBITION PREVENTS THE PARALYSIS INDUCED BY BOTULINUM NEUROTOXINS
RESULTS FROM A DOUBLE-BLIND AND OPEN-LABEL PHASE 3 STUDY OF A NOVEL LIQUID FORMULATION OF ABOBOTULINUMTOXINA (DYSPORT) IN THE TREATMENT OF CERVICAL DYSTONIA
BOTULINUM TOXIN TREATMENT FOR CERVICAL DYSTONIA IN THE UNITED KINGDOM: DISEASE BURDEN AND PATIENT NEEDS
APPROACH TO HAND TREMORS
THE COL CAP CONCEPT: OPTIMIZING THE TREATMENT OF CERVICAL DYSTONIA WITH BOTULINUM NEUROTOXIN: VOLUME MEASUREMENTS OF M. OBLIQUUS CAPITIS INFERIOR IN 56 PATIENTS WITH AND 23 WITHOUT TORTICAPUT
LONG-TERM EFFECTS OF HIGH DOSES OF INCOBOTULINUMTOXINA (XEOMIN) FOR TREATMENT OF SPASTICITY
MECHANISMS OF ACTION OF BOTULINUM NEUROTOXIN TYPE C: AN IN VIVO STUDY
BOTULINUM TOXIN TYPE A (INCOBOTULINUMTOXINA) FOR MUSCLE CRAMPS ASSOCIATED WITH DIABETIC NEUROPATHY: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
ALS DYSPHAGIA: DIFFERENT BONT/A RESPONSE FOR DIFFERENT PATHOPHYSIOLOGY
PATIENT SATISFACTION WITH ONABOTULINUMTOXINA TREATMENT OF GLABELLAR AND LATERAL CANTHAL LINES EVALUATED USING THE FLSQ: A NEW PATIENT-REPORTED OUTCOME MEASURE
BOTULINUM TOXINS FOR FOCAL DYSTONIAS: AN UPDATE OF 7 COCHRANE SYSTEMATIC REVIEWS
BOTULINUM NEUROTOXIN INJECTIONS FOR OROMANDIBULAR DYSTONIAS
EFFECTS OF A SYNTAXIN-SPECIFIC BOTULINUM NEUROTOXIN TYPE C ON MICE
EMG-GUIDED INJECTION OF BOTULINUM TOXIN A IN THE TREATMENT OF ILIOPSOAS SPASTICITY
BONT COMPLEXES AND THEIR JOURNEY TOWARD THE NERVOUS SYSTEM
SWEAT REDUCTION DEPENDING ON BOTULINUM NEUROTOXIN CONCENTRATION: A RANDOMIZED, DOUBLE-BLIND STUDY
THE COMCAL TO FACILITATE THE COMMUNICATION BETWEEN PHYSICIANS AND PHYSIOTHERAPISTS IN BOTULINUM NEUROTOXIN THERAPY OF SPASTICITY
NEUTRALIZING ANTIBODIES DIRECTED AGAINST BOTULINUM NEUROTOXIN TYPES A AND B HEAVY AND LIGHT CHAINS
SATISFACTION WITH BOTULINUM TOXIN TREATMENT FOR CERVICAL DYSTONIA, BLEPHAROSPASM, OR POSTSTROKE SPASTICITY: RESULTS FROM STRUCTURED PATIENT SURVEYS
EFFECT OF PAPAVERINE ON NEUROSPHERES
STATUS OF RECOMBINANT VACCINES AGAINST BOTULINUM NEUROTOXINS
EFFICACY AND SAFETY OF ONABOTULINUMTOXINA TREATMENT OF FOREHEAD LINES: A RANDOMIZED, CONTROLLED, DOSE-RANGING TRIAL
DEVELOPMENT OF A RATING SCALE
STRUCTURAL STUDIES OF BOTULINUM NEUROTOXIN BINDING TO PROTEIN AND GANGLIOSIDE RECEPTORS
PRIMARY SPEECH-INDUCED LINGUAL DYSTONIA: A RARE FOCAL DYSTONIA – TWO FURTHER CASES OF ILLNESS
DISASSOCIATION MECHANISM OF PROGENITOR COMPLEX OF BOTULINUM NEUROTOXIN SEROTYPE E
APPLIED ANATOMY FOR FACIAL INJECTIONS
PILOT STUDY TO ESTABLISH PROOF OF PRINCIPLE FOR THE USE OF ONABOTULINUMTOXINA (BOTOX) IN THE TREATMENT OF NOCTURNAL BRUXISM WITH ASSOCIATED CRANIOFACIAL PAIN
EGA PREVENTS THE NEURONAL TOXICITY OF BONT/A AND BONT/B
EVIDENCE-BASED REVIEW OF SAFETY AND EFFICACY OF BOTULINUM NEUROTOXIN IN CEREBRAL PALSY
BASELINE CHARACTERISTICS OF PATIENTS FROM A PHASE 3 PROGRAM TO ASSESS ABOBOTULINUMTOXINA (DYSPORT) IN THE TREATMENT OF SPASTICITY AND FUNCTIONAL IMPAIRMENTS IN CHILDREN WITH DYNAMIC EQUINUS FOOT DEFORMITY DUE TO CEREBRAL PALSY
HOW BOTULINUM TREATMENT OF ONE MUSCLE ONLY MAY REDUCE SPASTICITY OF A WHOLE LIMB
BOTULINUM TOXIN IN THE MANAGEMENT OF BLEPHAROSPASM: INITIAL AND SUBSEQUENT INJECTIONS—HOW DO WE MODIFY THE APPROACH TO OPTIMIZE OUTCOMES?
BOTULINUM NEUROTOXIN FOR NEUROGENIC THORACIC OUTLET SYNDROME
PATIENT SATISFACTION AND SAFETY OF 4402 GLABELLAR TREATMENTS WITH ONABOTULINUMTOXINA OVER 5 OR MORE YEARS
USE OF BOTULINUM TOXIN IN NONDYSTONIC DISORDERS
IMPROVEMENT OF FUNCTIONAL STATE OF THE BRAIN AS EFFECT OF TREATMENT OF GENERALIZED SPASTICITY WITH HIGH DOSES OF INCOBOTULINUMTOXINA (XEOMIN) IN PATIENTS IN A VEGETATIVE STATE
EFFECTS OF BOTULINUM TOXIN TREATMENT ON DYSTONIC, SPASTIC GAIT
A STUDY TO ASSESS RELIEF OF PAIN ASSOCIATED WITH SPASTICITY IN PATIENTS WITH POST-STROKE LOWER LIMB SPASTICITY TREATED WITH BOTULINUM TOXIN TYPE A (BONT-A) (RELIEF)
BOTULINUM TOXIN TREATMENT OF BRUXISM IN DEMENTIA
CARPAL TUNNEL SYNDROME RELIEF AFTER ESSENTIAL HAND TREMOR TREATMENT WITH BOTULINUM TOXIN
WHAT PRECEDES MOVEMENT DISORDER ONSET IN BLEPHAROSPASM?
CONTROVERSIES AND UNRESOLVED ISSUES IN USE OF BONT-1
DEVELOPMENT OF AN ELECTROCHEMILUMINESCENT ASSAY TO SUPPORT HIGH-THROUGHPUT SCREENING FOR BOTULINUM NEUROTOXIN SEROTYPE A (BONT/A) INHIBITORS
OPTIMIZING OUTCOMES WITH ADJUNCTIVE THERAPY FOR PEOPLE WITH CEREBRAL PALSY
CHARACTERIZING THE INTERACTION OF BOTULINUM NEUROTOXIN TYPE A WITH RAT AND HUMAN SV2C
GANGLIOSIDE TRAFFICKING AND ANTIGANGLIOSIDE ANTIBODIES
ONABOTULINUMTOXINA IMPROVES PAIN IN POSTSTROKE SPASTICITY PATIENTS: FINDINGS FROM A RANDOMIZED CONTROLLED TRIAL
ABOUT THE DISAPPEARANCE AND PECULIAR REAPPEARANCE OF BONT/A
FOODBORNE BOTULISM IN 2 ADULTS NOT TREATED BY ANTISERUM
DEPRESSION: BOTULINUM TOXIN ENTERS THE FIELD OF PSYCHIATRY
DO CLINICALLY EQUIVALENT DOSING RATIOS EXIST BETWEEN DIFFERENT FORMULATIONS OF BOTULINUM NEUROTOXIN A IN THE TREATMENT OF ADULT SPASTICITY, DYSTONIA, BLEPHAROSPASM, AND HEMIFACIAL SPASM: A SYSTEMATIC REVIEW
BOTULINUM NEUROTOXIN TYPE A AFFECTS MUSCLE CELLS BUT NOT MUSCLE-DERIVED FIBROBLASTS
MULTICENTER PROSPECTIVE COHORT STUDY ON PATIENT SATISFACTION AFTER INCOBOTULINUMTOXINA INJECTION IN CERVICAL DYSTONIA